Xianglin Hu1,2, Wending Huang1,2, Zhengwang Sun1,2, Hui Ye3, Kwong Man4, Qifeng Wang5, Yangbai Sun1,2, Wangjun Yan1,2. 1. Department of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032 China. 2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032 China. 3. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390 USA. 4. Department of General Surgery, University Hospital of Macau University of Science and Technology, Macau, 999078 China. 5. Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032 China.
Abstract
Background: Bone metastasis (BM) and skeletal-related events (SREs) happen to advanced lung cancer (LC) patients without warning. LC-BM patients are often passive to BM diagnosis and surgical treatment. It is necessary to guide the diagnosis and treatment paradigm for LC-BM patients from reactive medicine toward predictive, preventive, and personalized medicine (PPPM) step by step. Methods: Two independent study cohorts including LC-BM patients were analyzed, including the Surveillance, Epidemiology, and End Results (SEER) cohort (n = 203942) and the prospective Fudan University Shanghai Cancer Center (FUSCC) cohort (n = 59). The epidemiological trends of BM in LC patients were depicted. Risk factors for BM were identified using a multivariable logistic regression model. An individualized nomogram was developed for BM risk stratification. Personalized surgical strategies and perioperative care were described for FUSCC cohort. Results: The BM incidence rate in LC patients grew (from 17.53% in 2010 to 19.05% in 2016). Liver metastasis was a significant risk factor for BM (OR = 4.53, 95% CI = 4.38-4.69) and poor prognosis (HR = 1.29, 95% CI = 1.25-1.32). The individualized nomogram exhibited good predictive performance for BM risk stratification (AUC = 0.784, 95%CI = 0.781-0.786). Younger patients, males, patients with high invasive LC, and patients with other distant site metastases should be prioritized for BM prevention. Spine is the most common site of BM, causing back pain (91.5%), pathological vertebral fracture (27.1%), and difficult walking (25.4%). Spinal surgery with personalized spinal reconstruction significantly relieved pain and improved daily activities. Perioperative inflammation, immune, and nutrition abnormities warrant personalized managements. Radiotherapy needs to be recommended for specific postoperative individuals. Conclusions: The presence of liver metastasis is a strong predictor of LC-BM. It is recommended to take proactive measures to prevent BM and its SREs, particularly in young patients, males, high invasive LC, and LC with liver metastasis. BM surgery and perioperative management are personalized and required. In addition, adjuvant radiation following separation surgery must also be included in PPPM-guided management. Supplementary Information: The online version contains supplementary material available at 10.1007/s13167-022-00270-9.
Background: Bone metastasis (BM) and skeletal-related events (SREs) happen to advanced lung cancer (LC) patients without warning. LC-BM patients are often passive to BM diagnosis and surgical treatment. It is necessary to guide the diagnosis and treatment paradigm for LC-BM patients from reactive medicine toward predictive, preventive, and personalized medicine (PPPM) step by step. Methods: Two independent study cohorts including LC-BM patients were analyzed, including the Surveillance, Epidemiology, and End Results (SEER) cohort (n = 203942) and the prospective Fudan University Shanghai Cancer Center (FUSCC) cohort (n = 59). The epidemiological trends of BM in LC patients were depicted. Risk factors for BM were identified using a multivariable logistic regression model. An individualized nomogram was developed for BM risk stratification. Personalized surgical strategies and perioperative care were described for FUSCC cohort. Results: The BM incidence rate in LC patients grew (from 17.53% in 2010 to 19.05% in 2016). Liver metastasis was a significant risk factor for BM (OR = 4.53, 95% CI = 4.38-4.69) and poor prognosis (HR = 1.29, 95% CI = 1.25-1.32). The individualized nomogram exhibited good predictive performance for BM risk stratification (AUC = 0.784, 95%CI = 0.781-0.786). Younger patients, males, patients with high invasive LC, and patients with other distant site metastases should be prioritized for BM prevention. Spine is the most common site of BM, causing back pain (91.5%), pathological vertebral fracture (27.1%), and difficult walking (25.4%). Spinal surgery with personalized spinal reconstruction significantly relieved pain and improved daily activities. Perioperative inflammation, immune, and nutrition abnormities warrant personalized managements. Radiotherapy needs to be recommended for specific postoperative individuals. Conclusions: The presence of liver metastasis is a strong predictor of LC-BM. It is recommended to take proactive measures to prevent BM and its SREs, particularly in young patients, males, high invasive LC, and LC with liver metastasis. BM surgery and perioperative management are personalized and required. In addition, adjuvant radiation following separation surgery must also be included in PPPM-guided management. Supplementary Information: The online version contains supplementary material available at 10.1007/s13167-022-00270-9.
Authors: Ori Barzilai; Ilya Laufer; Adam Robin; Ran Xu; Yoshiya Yamada; Mark H Bilsky Journal: Oper Neurosurg (Hagerstown) Date: 2019-03-01 Impact factor: 2.703
Authors: Giuseppe Di Perna; Fabio Cofano; Cristina Mantovani; Serena Badellino; Nicola Marengo; Marco Ajello; Ludovico Maria Comite; Giuseppe Palmieri; Fulvio Tartara; Francesco Zenga; Umberto Ricardi; Diego Garbossa Journal: J Bone Oncol Date: 2020-09-26 Impact factor: 4.072
Authors: Laurens Bollen; Sander P D Dijkstra; Ronald H M A Bartels; Alexander de Graeff; Davey L H Poelma; Thea Brouwer; Paul R Algra; Jos M A Kuijlen; Monique C Minnema; Claudia Nijboer; Christa Rolf; Tebbe Sluis; Michel A M B Terheggen; Alexandra C M van der Togt-van Leeuwen; Yvette M van der Linden; Walter Taal Journal: Eur J Cancer Date: 2018-10-15 Impact factor: 9.162
Authors: Pavol Zubor; Zuzana Dankova; Zuzana Kolkova; Veronika Holubekova; Dusan Brany; Sandra Mersakova; Marek Samec; Alena Liskova; Lenka Koklesova; Peter Kubatka; Jan Bujnak; Karol Kajo; Milos Mlyncek; Frank A Giordano; Olga Golubnitschaja Journal: Cancers (Basel) Date: 2020-05-20 Impact factor: 6.639
Authors: Katie L Spencer; Joanne M van der Velden; Erin Wong; Enrica Seravalli; Arjun Sahgal; Edward Chow; Jorrit-Jan Verlaan; Helena M Verkooijen; Yvette M van der Linden Journal: J Natl Cancer Inst Date: 2019-10-01 Impact factor: 13.506